dementia

In the Lab Andrew Joseph

Study: Rare genetic mutation appears to have protected second person from early Alzheimer’s

Health Kay Lazar — Boston Globe

STAT Plus: Cracking an intriguing secret of centenarians: Why so few are ravaged by Alzheimer’s disease

The Readout LOUD Damian Garde, Meg Tirrell and Adam Feuerstein

Listen: Lilly’s Alzheimer’s success, a milestone FDA approval, & Moderna’s shrinking business

Politics Rachel Cohrs

STAT Plus: New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

In the Lab Jonathan Wosen

Don’t ignore potential microbial causes of Alzheimer’s and other chronic diseases, researchers say

Biotech Damian Garde

STAT Plus: For Eli Lilly’s head scientist, Alzheimer’s results cap a 25-year scientific quest

Biotech Matthew Herper and Adam Feuerstein

STAT Plus: Eli Lilly’s Alzheimer’s therapy slowed patients’ rate of cognitive decline, data show

Biotech Adam Feuerstein and Damian Garde

STAT Plus: What to know about the upcoming readout of Eli Lilly’s experimental Alzheimer’s therapy

The Readout LOUD Damian Garde, Meg Tirrell and Adam Feuerstein

Listen: Explaining the E.U.’s pharma overhaul, Lilly’s booming business, & a long-awaited drug approval

Biotech Damian Garde

STAT Plus: Alnylam’s ‘upstream’ Alzheimer’s treatment shows early promise

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Lilly expects Medicare to back down on Alzheimer’s drug coverage; key senators change insulin cap proposal

Politics John Wilkerson

STAT Plus: FDA’s Califf talks cell and gene therapies, abortion pill, Alzheimer’s drugs

In the Lab Usha Lee McFarling

In the whitewashed world of Alzheimer’s research, one scientist is on a quest to understand the diversity of brains

Politics Sarah Owermohle

STAT Plus: Senators interrogate health secretary Becerra on Alzheimer’s drug coverage

Health Jonathan Wosen

Stanford scientist who broke genome sequencing record on what faster diagnoses mean for patients

Pharmalot Ed Silverman

STAT Plus: Veterans Health Administration will cover the newest Alzheimer’s drug

The Readout LOUD Damian Garde, Meg Tirrell and Adam Feuerstein

Listen: Robert Califf on how drugs get approved, plus the nascent revolution in obesity

First Opinion Steven G. Smith

An intimate look at dementia — and the emotional toll it takes on family and caregivers

Biotech Adam Feuerstein and Damian Garde

STAT Plus: FDA’s Billy Dunn, key figure in approval of Aduhelm, to leave agency

Politics Rachel Cohrs

STAT Plus: Medicare advisers suggest tweaks to coverage process for Alzheimer’s drugs

Biotech Adam Feuerstein

STAT Plus: Eisai reports first U.S. sales of newly approved treatment for Alzheimer’s disease

The Readout LOUD Adam Feuerstein and Meg Tirrell

Listen: George Scangos’ retirement, annual Covid vaccines, an Alzheimer’s drug rejection

Adam's Take Adam Feuerstein

STAT Plus: New results show Cassava’s Alzheimer’s drug has placebo-like efficacy

Biotech Adam Feuerstein

STAT Plus: FDA rejects Lilly’s bid for accelerated approval for its Alzheimer’s drug

Biotech Jason Mast

STAT Plus: Regeneron’s George Yancopoulos admits some regret, but ‘I don’t apologize’

Pharmalot Ed Silverman

STAT Plus: Physicians group urges FDA to convene expert panel before finally approving an Alzheimer’s drug

Biotech Adam Feuerstein

STAT Plus: FDA approves Alzheimer’s drug shown to moderately slow cognitive decline in early stages of the disease

The Readout LOUD Damian Garde, Meg Tirrell and Adam Feuerstein

Listen: #JPM23, the future of Alzheimer’s, & rising Covid variants

Biotech Jason Mast

STAT Plus: As FDA considers new Alzheimer’s drug, a case study details safety concerns